ライフサイエンスコーパス: solid organ transplant

1 event cytomegalovirus (CMV) infections after solid organ transplant.

2 s of primary cutaneous T-cell lymphoma after solid organ transplant.

3 the short- and long-term clinical outcome of solid organ transplant.

4 s) were saved to date during the 25 years of solid-organ transplant.

5 typically related to immunomodulation during solid-organ transplant.

6 plants and show great promise for women with solid-organ transplant.

7 he most common opportunistic infection after solid-organ transplant.

8 nd 2018 with a diagnosis of amyloidosis post solid-organ transplant.

9 gs) in both murine and human recipients of a solid-organ transplant.

10 the major obstacle for long-term survival of solid organ transplants.

11 nt recipients and may be applicable to other solid organ transplants.

12 plant are similar to those reported in other solid organ transplants.

13 antibodies in acute and chronic rejection of solid organ transplants.

14 ts with cancer or recipients of stem cell or solid organ transplants.

15 ansplantation of hematopoietic stem cells or solid organ transplants.

16 ffects on graft survival in several types of solid organ transplants.

17 h chronic hepatitis E who were recipients of solid-organ transplants.

18 tion is associated with the deterioration of solid-organ transplants.

19 ia among recipients of hematopoietic-cell or solid-organ transplants.

20 of patients, including HIV infection (45%), solid organ transplant (26%), and cirrhosis (22%).

21 is the first description of amyloidosis post solid-organ transplant; 30 cases among 5112 amyloid pati

22 KP infections occurred more frequently among solid organ transplant (31%) and dialysis (17%) patients

23 he records of 59 patients who had received a solid-organ transplant (37 kidney-transplant recipients,

24 he registry linkages yielded data on 175,732 solid organ transplants (58.4% for kidney, 21.6% for liv

25 Patients listed or being evaluated for solid organ transplant after January 26, 2018, were educ

26 Four patients were immunosuppressed after solid organ transplant and all were receiving blood pres

27 plications for sensitized patients receiving solid organ transplants and antibody-mediated rejection

28 apy for ESBL-producing Enterobacteriaceae in solid organ transplants and MCS device recipients are es

29 d 123 from the literature), 63 had undergone solid-organ transplant and 39 had human immunodeficiency

30 Thirty-five patients with a solid-organ transplant and chronic hepatitis E virus inf

31 tion of C. difficile in hematology-oncology, solid organ transplant, and HIV-infected patients.

32 inical trials to treat patients with cancer, solid organ transplants, and autoimmune diseases.

33 ations, including patients with neutropenia, solid organ transplants, and nonurologic surgery.

34 the liver less prone to rejection than other solid organ transplants, and reaction to local injury, s

35 to induce rejection compared with most other solid organ transplants, and simultaneous transplantatio

36 g transplantation is among the lowest of all solid-organ transplants, and current diagnostic tests of

37 l infarction, stroke, hemorrhagic shock, and solid organ transplant are particularly prone to cause I

38 Outcomes after solid organ transplants are improving; for adult patient

39 The goals of tolerance in patients with solid organ transplants are to eliminate the lifelong ne

40 omen of reproductive age who have received a solid-organ transplant are at risk for unplanned pregnan

41 We included pediatric recipients of solid organ transplants at the Hospital for Sick Childre

42 equirement for immunosuppression compared to solid organ transplants because of the inherent immune p

43 ded patients with end-stage renal disease or solid organ transplants because very few are uninsured.

44 repository, in parallel with systems used by solid organ transplant centers.

45 ant recipients that in turn has impacted the solid organ transplant community as well.

46 w one of the most common bacterial causes of solid-organ transplant donor-derived infection reported

47 this retrospective analysis of UNOS data for solid-organ transplant during a 25-year period (Septembe

48 n 2 million life-years were saved to date by solid-organ transplants during a 25-year study period.

49 umoral rejection is the most common cause of solid organ transplant failure.

50 From 1999 to 2010, we performed solid organ transplants for 1331 recipients at our insti

51 The charts of all patients receiving a solid organ transplant from 1990-2008 evaluated in the d

52 were seen in recipients receiving noncardiac solid organ transplants from simvastatin-treated donors.

53 ssessed graft survival through 1 year of all solid organs transplanted from 370 donors who had been r

54 d trial, recipients of hematopoietic-cell or solid-organ transplants (>=18 years of age, with CMV rea

55 measurements as infection risk markers after solid organ transplant has not been fully investigated.

56 inimization and avoidance protocols for post-solid organ transplant have been developed.

57 Immunosuppressed patients with solid organ transplants have an increased risk for nonme

58 partners, bridges research in the fields of solid organ transplant, hematopoietic cell transplant, a

59 lant failure or rejection (HR 3.2), previous solid organ transplant (HR 1.7), and several comorbiditi

60 ctious disease consultation in recipients of solid organ transplant is associated with increased LOS

61 Ab-mediated rejection (AMR) of solid organ transplants is characterized by intragraft m

62 on of continuous distribution models for all solid organ transplants may allow for minimization of th

63 thritis (n = 97), hematopoietic stem-cell or solid organ transplant (n = 26), or a general cohort of

64 Recipients of nonkidney solid organ transplants (nkSOT) are living longer, and 1

65 e to ten-fold risk (25 to 30 fold risk after solid organ transplant) of colorectal cancer (CRC) than

66 Receiving a solid organ transplant owing to late-stage organ failure

67 sed by Nocardia thailandica in a 66-year-old solid organ transplant patient from Connecticut, which w

68 We reviewed 1593 solid organ transplant patients and reported the frequen

69 unoglobulin was identified in only 3% of all solid organ transplant patients pretransplant (n=34).

70 ill, oncologic or stem cell transplant, and solid organ transplant patients showed a relationship be

71 One hundred and fifty-three solid organ transplant patients were enrolled, including

72 We studied six cases of CMV replication in solid organ transplant patients whose genotypic testing

73 Solid organ transplant patients with first episode of CM

74 (Carbapenem-Resistant Enterobacteriaceae in Solid Organ Transplant Patients) has provided pivotal da

75 In solid organ transplant patients, global suppression of i

76 emerged as a cause of persistent diarrhea in solid organ transplant patients.

77 romised individuals, such as bone marrow and solid organ transplant patients.

78 with medication, could predict adherence in solid organ transplant patients.

79 skin malignancies and emotional distress in solid organ transplant patients.

80 ed all cryptosporidiosis cases identified in solid organ transplanted patients between 2006 and 2010

81 trated efficacy in preventing CMV disease in solid-organ transplant patients as well as congenital di

82 ional markers aimed at identifying long-term solid-organ transplant patients at high risk of developi

83 We assessed kidney function and histology in solid-organ transplant patients during HEV infection.

84 been used to treat chronic HEV infection in solid-organ transplant patients with some success.

85 th significant morbidity and mortality among solid-organ transplant patients, but approaches to diagn

86 ating chronic hepatitis E virus infection in solid-organ transplant patients.

87 cies in ORF1 and the outcome of infection in solid-organ transplant patients.

88 g transplantation lags behind that for other solid organ transplants, primarily because of allograft

89 ew will discuss key studies in the different solid organ transplants, recent reports of adverse event

90 six cases of PTLD were identified with 1392 solid-organ transplant recipient controls.

91 even patients (10 with HIV infection and one solid-organ transplant recipient) developed tuberculosis

92 life-years were saved (observed to date) per solid-organ transplant recipient.

93 conducted a retrospective cohort study of US solid organ transplant recipients (1997-2007).

94 We reported 47 solid organ transplant recipients (41 kidneys) with cryp

95 The increased incidence of skin cancers in solid organ transplant recipients (OTR) has been well es

96 reported an increased risk of skin cancer in solid organ transplant recipients (OTRs), no study has e

97 ntibody response to the 2009-H1N1 vaccine in solid organ transplant recipients (SOTR) and its clinica

98 s on the use of generic immunosuppression in solid organ transplant recipients (SOTR) based on a revi

99 De novo solid organ transplant recipients (SOTR) have a steep le

100 Solid organ transplant recipients (SOTR) with a pretrans

101 Solid organ transplant recipients (SOTr) with coronaviru

102 The number of solid organ transplant recipients (SOTR), and their life

103 enza vaccine effectiveness is not optimal in solid organ transplant recipients (SOTR).

104 is a significant opportunistic infection in solid organ transplant recipients (SOTR).

105 or contributor to morbidity and mortality in solid organ transplant recipients (SOTRs).

106 view available data on coccidioidomycosis in solid organ transplant recipients and candidates seeking

107 iabetes mellitus (PTDM) affects up to 50% of solid organ transplant recipients and compromises long-t

108 e multiple risk factors for CNS processes in solid organ transplant recipients and establishes a time

109 Diabetes is prevalent among solid organ transplant recipients and is universal among

110 excess risk are similar to those observed in solid organ transplant recipients and patients with auto

111 tion of pretransplantation HLA antibodies in solid organ transplant recipients and, in particular, th

112 Solid organ transplant recipients are at increased risk

113 Solid organ transplant recipients are at risk for potent

114 as treatment of chronic hepatitis C virus in solid organ transplant recipients are limited.

115 VZV immunization of pediatric solid organ transplant recipients confers sustained sero

116 -scale retrospective study that included 255 solid organ transplant recipients confirms that ribaviri

117 Pediatric solid organ transplant recipients demonstrate worse over

118 testing novel immunotherapy combinations in solid organ transplant recipients designed to uncouple a

119 n addition, a significant number of nonrenal solid organ transplant recipients develop chronic kidney

120 Another cluster of solid organ transplant recipients developed encephalitis

121 Solid organ transplant recipients enrolled in an interna

122 ssociated cluster of febrile illness among 3 solid organ transplant recipients from a common donor.

123 Solid organ transplant recipients from HHV-8 endemic reg

124 TICIPANTS: Cohort study using linked data on solid organ transplant recipients from the US Scientific

125 Solid organ transplant recipients have a high incidence

126 Solid organ transplant recipients have an increased risk

127 Solid organ transplant recipients have elevated cancer r

128 Solid organ transplant recipients have heightened risk f

129 Solid organ transplant recipients have increased risk fo

130 ntions to prevent nonmelanoma skin cancer in solid organ transplant recipients have not been summariz

131 ntified a Swedish population-based cohort of solid organ transplant recipients in the National Patien

132 ecipients, which contains information on all solid organ transplant recipients in the United States,

133 We report four cases of COVID-19 in solid organ transplant recipients including recipients o

134 atforms to support the postoperative care of solid organ transplant recipients is evolving.

135 Currently, 1 in 6 pediatric solid organ transplant recipients is hospitalized with a

136 Solid organ transplant recipients may be at a high risk

137 eatment outcomes during CMV infection in 291 solid organ transplant recipients receiving valganciclov

138 n-resistant Enterococcus faecium (LR-VRE) in solid organ transplant recipients remain uncommon, they

139 ng Enterobacteriaceae and CRE carriage among solid organ transplant recipients to inform management o

140 Treatment failure or relapse is common in solid organ transplant recipients treated for cytomegalo

141 cancer was assessed among 118,440 Caucasian solid organ transplant recipients using multivariate Cox

142 The impact of these therapies in solid organ transplant recipients was not assessed in cl

143 Solid organ transplant recipients were identified within

144 omes associated with low PA in adult single, solid organ transplant recipients were included.

145 high-throughput gene expression datasets of solid organ transplant recipients were retrieved from th

146 Non-lung solid organ transplant recipients who developed NSCLC ha

147 In solid organ transplant recipients who presented at our i

148 Approximately 33.6% of nondiabetic solid organ transplant recipients who received tacrolimu

149 andemic of SARS-CoV-2, there is concern that solid organ transplant recipients will be particularly v

150 In contrast, reports of solid organ transplant recipients with clinical features

151 ates that elevated osteoprotegerin levels in solid organ transplant recipients with CMV infection may

152 ms, clinical severity, and disease course in solid organ transplant recipients with COVID-19, includi

153 We herein report our initial experience with solid organ transplant recipients with SARS-CoV-2 infect

154 75] days before ICU admission), 4 (10%) were solid organ transplant recipients, and 10 (27%) were inf

155 view the current status of CMV resistance in solid organ transplant recipients, and provide diagnosti

156 ears to be safe and immunogenic in pediatric solid organ transplant recipients, but there are few dat

157 In this study of 649 solid organ transplant recipients, followed prospectivel

158 erebral vasculature that occurs in 0.5-5% of solid organ transplant recipients, most commonly associa

159 Among other solid organ transplant recipients, no significant improv

160 ctivation can cause significant morbidity in solid organ transplant recipients, particularly BK virus

161 hough diarrhea is a frequent complaint among solid organ transplant recipients, the contribution of i

162 tors for invasive mold infections among 1101 solid organ transplant recipients, thereby strengthening

163 Solid organ transplant recipients, who are medically imm

164 er phase II trial, 152 treatment-naive adult solid organ transplant recipients, with CD20(+) PTLD unr

165 D) is an increasingly important diagnosis in solid organ transplant recipients, with rising incidence

166 andomized trials of eHealth interventions in solid organ transplant recipients.

167 ing the incidence of rejection in HIV-to-HIV solid organ transplant recipients.

168 y of cases of antibody-mediated rejection in solid organ transplant recipients.

169 stemic non-Hodgkin lymphoma (NHL) in 288 029 solid organ transplant recipients.

170 on growth and safety parameters in pediatric solid organ transplant recipients.

171 ell recognized but uncommon complications in solid organ transplant recipients.

172 nd a leading cause of cancer mortality among solid organ transplant recipients.

173 iclovir for cytomegalovirus (CMV) disease in solid organ transplant recipients.

174 a major cause of graft loss and mortality in solid organ transplant recipients.

175 ysis over an 18-month period of hospitalized solid organ transplant recipients.

176 ients receiving immunosuppressing drugs, and solid organ transplant recipients.

177 infectious disease-related complications in solid organ transplant recipients.

178 ting for chronic hepatitis in some pediatric solid organ transplant recipients.

179 interventions to support self-management in solid organ transplant recipients.

180 endations are likely to be relevant to other solid organ transplant recipients.

181 ory affects posttransplantation mortality in solid organ transplant recipients.

182 to these viruses are reported only in 1% of solid organ transplant recipients.

183 t of early- and late-onset PTLD in pediatric solid organ transplant recipients.

184 for improving the cardiovascular outcomes of solid organ transplant recipients.

185 new causative agent of chronic hepatitis in solid organ transplant recipients.

186 may have a role in renal dysfunction in some solid organ transplant recipients.

187 ation with opportunistic infections (OIs) in solid organ transplant recipients.

188 treatment failure during anti-CMV therapy in solid organ transplant recipients.

189 nt medication is a significant problem among solid organ transplant recipients.

190 ify risk factors of Hodgkin lymphoma (HL) in solid organ transplant recipients.

191 t cause of morbidity, mortality, and cost in solid organ transplant recipients.

192 OVID-19 has the potential to severely impact solid organ transplant recipients.

193 vity (PA) and its correlates and outcomes in solid organ transplant recipients.

194 both the hematology-oncology population and solid organ transplant recipients.

195 ts to prevent nonmelanoma skin cancers among solid organ transplant recipients.

196 l-based adjunct immunosuppressive therapy in solid organ transplant recipients.

197 Hematopoietic-cell or solid-organ transplant recipients >=12 years old with RR

198 and risk factors of obesity among pediatric solid-organ transplant recipients (heart, lung, liver, k

199 and risk factors of obesity among pediatric solid-organ transplant recipients (heart, lung, liver, k

200 umatoid arthritis (n = 199), 9.0 to 20.0% in solid-organ transplant recipients (n = 197), 0% to 5.8%

201 Solid-organ transplant recipients (OTRs) are at an incre

202 Immunosuppression (IS), such as in solid-organ transplant recipients (SOTRs) and patients w

203 Solid-organ transplant recipients (SOTRs) are at greater

204 0 fresh CMV DNA-positive plasma samples from solid-organ transplant recipients (SOTRs) were tested.

205 ted to occur during transitions of care, and solid-organ transplant recipients are at an increased ri

206 Solid-organ transplant recipients are at increased risk

207 ical trials with expanded T(regs) in T1D and solid-organ transplant recipients are limited by poor T(

208 A total of 840 solid-organ transplant recipients at risk for CMV infect

209 ta of pandemic influenza A H1N1 infection in solid-organ transplant recipients have been described, b

210 Moreover, in solid-organ transplant recipients with active CMV infect

211 We describe four solid-organ transplant recipients with donor-derived Wes

212 the effects of ribavirin as monotherapy for solid-organ transplant recipients with prolonged HEV vir

213 inhibitors, patients receiving hemodialysis, solid-organ transplant recipients, and patients with can

214 fluence susceptibility to CMV replication in solid-organ transplant recipients, particularly in patie

215 onmelanoma skin cancer is well recognized in solid-organ transplant recipients, the risk of skin canc

216 CMV) disease remains an important problem in solid-organ transplant recipients, with the greatest ris

217 immunocompromised individuals, especially in solid-organ transplant recipients.

218 implementation, which was not seen in other solid-organ transplant recipients.

219 idence of cytomegalovirus (CMV) infection in solid-organ transplant recipients.

220 ital charges among lung transplant and other solid-organ transplant recipients.

221 dergoing nonurologic surgeries, and nonrenal solid-organ transplant recipients.

222 sed for cytomegalovirus (CMV) prophylaxis in solid-organ transplant recipients.

223 drug-resistant/recurrent cytomegalovirus in solid-organ transplant recipients.METHODSIn the present

224 Twenty-four solid-organ-transplant recipients with chronic hepatitis

225 Through linkage of the US solid organ transplant registry with 15 state/regional c

226 Suppression of solid-organ transplant rejection has traditionally focus

227 iew is to discuss the current and historical solid organ transplant-related disruptions in the supply

228 hoproliferative disease (PTLD) arising after solid organ transplant remains contentious.

229 -pollination and synergy between corneal and solid organ transplant research communities.

230 economics willingness-to-pay threshold to a solid organ transplant setting by coining a new metric:

231 Records of solid organ transplant (SOT) and hematopoietic cell tran

232 Data describing antibiotic allergies among solid organ transplant (SOT) and hematopoietic cell tran

233 cause of morbidity and mortality among both solid organ transplant (SOT) and hematopoietic stem cell

234 ous diseases physicians in persons receiving solid organ transplant (SOT) between May 2008 and Decemb

235 Solid organ transplant (SOT) candidates and recipients a

236 for exercise training in adult and children solid organ transplant (SOT) candidates and recipients a

237 In this cross-sectional study of solid organ transplant (SOT) candidates and recipients,

238 cal and molecular pretransplant screening in solid organ transplant (SOT) donors and recipients in no

239 Two groups were identified: the solid organ transplant (SOT) group (n = 15; 12 ITX and 3

240 s a potentially fatal disorder arising after solid organ transplant (SOT) or hematopoietic stem cell

241 ally ill coronavirus disease 2019 (COVID-19) solid organ transplant (SOT) patients are limited.

242 Despite annual immunization, solid organ transplant (SOT) patients remain at increase

243 responses to natural influenza infection in solid organ transplant (SOT) patients.

244 In the solid organ transplant (SOT) population, manifestations

245 Solid organ transplant (SOT) recipients are at elevated

246 Hematopoietic cell transplant (HCT) and solid organ transplant (SOT) recipients are at increased

247 Solid organ transplant (SOT) recipients are at risk for

248 Solid organ transplant (SOT) recipients are at risk of n

249 Although solid organ transplant (SOT) recipients are particularly

250 tis jirovecii pneumonia (PJP) prophylaxis in solid organ transplant (SOT) recipients at increased ris

251 ause severe infections in seronegative adult solid organ transplant (SOT) recipients but can be preve

252 Solid organ transplant (SOT) recipients comprise a large

253 In fall 2017, 3 solid organ transplant (SOT) recipients from a common do

254 ecific cytotoxic T lymphocytes (EBV-CTLs) to solid organ transplant (SOT) recipients has been shown s

255 Approximately 3%-10% of solid organ transplant (SOT) recipients in CRE-endemic a

256 , and immune responses in HIV-infected adult solid organ transplant (SOT) recipients on antiretrovira

257 ological response (SVR) in a large cohort of solid organ transplant (SOT) recipients with chronic HEV

258 e of immune reconstitution syndrome (IRS) in solid organ transplant (SOT) recipients with cryptococco

259 We sought to determine whether a subset of solid organ transplant (SOT) recipients with high likeli

260 ical characteristics, risks, and outcomes in solid organ transplant (SOT) recipients with zygomycosis

261 enteritis can cause intractable diarrhea in solid organ transplant (SOT) recipients, for which there

262 D-19 among immunosuppressed patients such as solid organ transplant (SOT) recipients, who are at pres

263 CMV) is an emerging and important problem in solid organ transplant (SOT) recipients.

264 ons have the potential to affect outcomes in solid organ transplant (SOT) recipients.

265 ug-resistant (XDR) Pseudomonas aeruginosa in solid organ transplant (SOT) recipients.

266 significant manifestation of zygomycosis in solid organ transplant (SOT) recipients.

267 disproportionately more severe disease among solid organ transplant (SOT) recipients.

268 own about COVID-19, including its effects on solid organ transplant (SOT) recipients.

269 a major cause of morbidity and mortality in solid organ transplant (SOT) recipients.

270 failure in adolescent and young adult (AYA) solid organ transplant (SOT) recipients.

271 s associated with morbidity and mortality in solid organ transplant (SOT) recipients.

272 utcomes associated with histoplasmosis after solid organ transplant (SOT), we report a large series o

273 med a multicenter, International analysis of solid organ transplant (SOT)-related primary central ner

274 n, affecting 0.04% to 3.5% of patients after solid organ transplant (SOT).

275 Sepsis is a serious complication of solid organ transplant (SOT).

276 erculosis infection (LTBI) is recommended in solid organ transplant (SOT).

277 lity after hematopoietic stem cell (HSCT) or solid organ transplant (SOT).

278 cer, human immunodeficiency virus (HIV), and solid organ transplant (SOT).

279 ad immunosuppression (120; 82.8%), including solid organ transplant (SOT; 33.8%), autoimmunity (15.9%

280 ncer (hematologic and solid tumor), HIV, and solid organ transplant (SOT; kidney and other).

281 Patients waitlisted for and recipients of solid organ transplants (SOT) are perceived to have a hi

282 gained over the years shows that, similar to solid organ transplants (SOT), human VCA can also develo

283 V) is an important pathogen in recipients of solid organ transplants (SOT).

284 reatment of latent tuberculosis infection in solid-organ transplant (SOT) candidates.

285 finger-stick DBS and plasma samples from 35 solid-organ transplant (SOT) patients.

286 Solid-organ transplant (SOT) recipients are considered t

287 econstitution inflammatory syndrome (IRS) in solid-organ transplant (SOT) recipients are not known.

288 ding bacteremia caused by these organisms in solid-organ transplant (SOT) recipients is lacking.

289 (IMI) among hematopoietic stem cell but not solid-organ transplant (SOT) recipients.

290 s posed by invasive biopsy for monitoring of solid organ transplants (SOTs).

291 Co-management with a solid organ transplant specialist is helpful for the mon

292 related outcomes across a range of different solid-organ transplant studies.

293 jection, which is in sharp contrast to other solid organ transplants, such as kidney, lung, and heart

294 ng a significant clinical problem across all solid organ transplants, there are limited therapeutics

295 inking hematopoietic chimerism induction and solid organ transplant tolerance, the mechanistic requir

296 how preexisting autoreactive T cells affect solid-organ transplants under these conditions is unknow

297 ividuals with inflammatory bowel diseases or solid-organ transplants, virome dynamics in allogeneic h

298 A panel of experts on CMV and solid organ transplant was convened by The Infectious Di

299 ransplants and reduced long-term survival of solid organ transplants, we hypothesized that convention

300 ent and Transplantation Network data, 28 051 solid organ transplants were performed in 2012.